Vera Therapeutics(VERA) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Third Quarter 2025 and Recent Business Highlights • Atacicept IgA nephropathy (IgAN) ORIGIN 3 trial primary endpoint results selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology (ASN) Kidney Week 2025 • Biologics License Application (BLA) submission through the Accelerated Approval Program for atacicept for the treatment of IgAN to U.S. FDA expected in Q4; potential U.S. commercial launch of atacicept in 2026 • Actively enrollin ...